This, and the fact that various agents were identified that already have been shown to be effective against KMT2A-rearranged acute leukemia, such as BCL-2 inhibitors [25,26], HDAC inhibitors [27,28,29], and SN-38 [21], clearly demonstrated the validity of our drug screens. Here, KMT2A is linked to acute leukemia.